# name
Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax compared with Turbuhaler in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

# metadata.dc.description.abstract[].value
The objective of this study was to estimate the economic impact of the introduction of DuoResp® Spiromax®, budesonide/formoterol fixed-dose combination (FDC), focusing on an increase in medication adherence due to an enhancement of the inhalation technique for the treatment of COPD patients in Spain and 5 regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. ...

# metadata.dc.relation.ispartof[].value
Clinicoeconomics and Outcomes Research, 2017, vol. 9, num. February, p. 127-137

# metadata.dc.source[].value
Articles publicats en revistes (Economia)

# metadata.dc.title[].value
Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax compared with Turbuhaler in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain